0000000000823377
AUTHOR
A. Bedogni
L’odontoiatria a misura del paziente con patologia osteometabolica a rischio di osteonecrosi delle ossa mascellari da farmaci.
L’osteonecrosi delle ossa mascellari (ONJ) da farmaci è una severa patologia odontoiatrica, recentemente defi nita come «una reazione avversa farmacocorrelata, caratterizzata dalla progressiva distruzione e necrosi dell’osso mandibolare e/o mascellare di soggetti esposti al trattamento con farmaci per cui sia accertato un aumentato rischio di malattia, in assenza di un pregresso trattamento radiante»1-3. I pazienti osteometabolici a rischio di sviluppare l’ONJ sono quelli sottoposti a terapia con bisfosfonati (in particolare aminobisfosfonati o Nitrogen-containing BisPhosphonate/NBP) e, più recentemente, con denosumab (anticorpo monoclonale anti-RANKL)4. Tali farmaci antiriassorbitivi carat…
Prevenzione e management odontoiatrico dei pazienti oncologici a rischio di osteonecrosi delle ossa mascellari da farmaci.
non disponibile
Comments on "diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus"
Letter to editor
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study
Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…
Epidemiology, clinical manifestations, risk-reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents
Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases, of surgica…
Pain management in osteonecrosis of jaw (ONJ): an orphan issue?
We performed a systematic review of oNJ literature with keyword and MeSH terms referred to pain and its treatment, on PubMed and other literature sources on 2014-2018 years. out of 2957 publications citing oNJ and published in the period, 350 papers reported about pain anyhow.
Osteonecrosis of jaw (onj): impact of italian patients, and role of italian physicians, dentists, and researchers in the growing evidence of a “new” disease
Purpose: Osteonecrosis of jaw (ONJ) is an uncommon but severe complication observed mostly in patients treated with bisphosphonates (BPs) for bone metastases, myeloma, osteoporosis (so called BRONJ, Bisphosphonate-Related Osteonecrosis of Jaw), but also with other drugs (bevacizumab, sunitinib, denosumab). The number of cases observed in Italy appears high in comparison with other countries and we present a review of several aspects of ONJ in Italy and the role of Italian health professionals and researchers on increasing knowledge and adequate reporting of ONJ phenomenon; Methods: Literature review about osteonecrosis of jaw (ONJ) with selection of Italian authors and publications, on year…